Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF.
Herbst R, Arkenau H, Calvo E, Bendell J, Penel N, Fuchs C, McNeely S, Rasmussen E, Wang H, Oliveira J, Ferry D, Chau I. Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF. Journal Of Clinical Oncology 2020, 38: 3089-3089. DOI: 10.1200/jco.2020.38.15_suppl.3089.Peer-Reviewed Original ResearchNon-small cell lung cancerPD-L1 protein expressionObjective response rateBiliary tract cancerProgression-free survivalClinical outcomesOverall survivalUrothelial carcinomaProtein expressionDako PD-L1 IHC 22C3 pharmDxAdvanced non-small cell lung cancerDay 1Phase 1a/b trialImmune checkpoint-related genesPD-L1 IHC 22C3 pharmDxPD-L1 negative tumorsPD-L1 positive tumorsMyeloid-derived suppressor cellsPD-L1 gene expressionTumor microenvironmentPanCancer Immune Profiling PanelImmune-related gene signatureImmune-related gene expressionBaseline tumor samplesGastroesophageal junction adenocarcinoma